{"References": [{"title": "Ivacaftor in patients with cystic fibrosis and a G551D mutation", "authors": "Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW", "journal": "New England Journal of Medicine", "year": "2011", "volumes": "365", "first page": "1663", "last page": "1672", "DOI": "10.1056/NEJMoa1105185"}, {"title": "A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial", "authors": "Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA", "journal": "The Lancet", "year": "2015", "volumes": "385", "first page": "1719", "last page": "1730", "DOI": "10.1016/S0140-6736(14)62020-7"}, {"title": "Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele", "authors": "Middleton PG, Mall MA, Dřevínek P, McKone EF, Polineni D, Asif S, Waltz D, Zhang S, Quon BS, Flume PA", "journal": "New England Journal of Medicine", "year": "2020", "volumes": "383", "first page": "2222", "last page": "2232", "DOI": "10.1056/NEJMoa2026511"}, {"title": "Tezacaftor-ivacaftor in residual-function heterozygous cystic fibrosis", "authors": "Quon BS, Flume PA, Middleton PG, Polineni D, Waltz D, Zhang S, Asif S, Dřevínek P, Mall MA, McKone EF", "journal": "American Journal of Respiratory and Critical Care Medicine", "year": "2018", "volumes": "198", "first page": "1444", "last page": "1453", "DOI": "10.1164/rccm.201806-1155OC"}, {"title": "Efficacy and safety of ivacaftor in patients aged 2–5 years with cystic fibrosis with a G551D mutation", "authors": "McColley SA, Rowe SM, Accurso FJ, Boyle MP, Dorkin HL, Durie PR, Goss CH, McCoy KS, McWilliams L, Ratjen F", "journal": "Lancet Respiratory Medicine", "year": "2014", "volumes": "2", "first page": "961", "last page": "968", "DOI": "10.1016/S2213-2600(14)70221-7"}, {"title": "Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with minimal function mutations", "authors": "Flume PA, Quon BS, Waltz D, Zhang S, Asif S, Dřevínek P, Mall MA, McKone EF, Middleton PG", "journal": "New England Journal of Medicine", "year": "2020", "volumes": "383", "first page": "2233", "last page": "2242", "DOI": "10.1056/NEJMoa2026512"}, {"title": "Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele: a phase 3 randomised, double-blind, placebo-controlled study", "authors": "Mall MA, Dřevínek P, McKone EF, Polineni D, Asif S, Waltz D, Zhang S, Quon BS, Flume PA, Middleton PG", "journal": "The Lancet", "year": "2020", "volumes": "396", "first page": "1407", "last page": "1418", "DOI": "10.1016/S0140-6736(20)32217-6"}, {"title": "Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele: a phase 3, randomised, double-blind, placebo-controlled study", "authors": "Middleton PG, Mall MA, Dřevínek P, McKone EF, Polineni D, Asif S, Waltz D, Zhang S, Quon BS, Flume PA", "journal": "The Lancet Respiratory Medicine", "year": "2020", "volumes": "8", "first page": "1185", "last page": "1196", "DOI": "10.1016/S2213-2600(20)30368-3"}, {"title": "Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles", "authors": "Quon BS, Flume PA, Waltz D, Zhang S, Asif S, Dřevínek P, Mall MA, McKone EF, Middleton PG", "journal": "New England Journal of Medicine", "year": "2020", "volumes": "383", "first page": "2210", "last page": "2221", "DOI": "10.1056/NEJMoa2026510"}, {"title": "Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele: a phase 3, randomised, double-blind, placebo-controlled study", "authors": "Dřevínek P, Mall MA, McKone EF, Polineni D, Asif S, Waltz D, Zhang S, Quon BS, Flume PA, Middleton PG", "journal": "The Lancet Respiratory Medicine", "year": "2020", "volumes": "8", "first page": "1197", "last page": "1208", "DOI": "10.1016/S2213-2600(20)30369-5"}]}